X hits on this document

121 views

0 shares

0 downloads

0 comments

42 / 61

Clinical Trials

LIDO Trial

Levosimendan 24 hr infiusionvs Dobutamine

203 Patients

Severe Decompensated HF, AHF, HF after CABG

Excluded if cardiogenic shock

Endpoints, increased CI (35% vs 25%) and reduced PCWP (28% vs 15%) in favor of Levosimendan

SURVIVE Trial

Levosimendan vs Dobutamine 24 hour therapy

1327 patients

Endpoints symptomatic relief and BNP

Levosimendan Greater reduction in BNP but no difference in symptomatic relief

Document info
Document views121
Page views121
Page last viewedSun Dec 04 04:40:07 UTC 2016
Pages61
Paragraphs503
Words1542

Comments